Bright Minds Biosciences Inc. reported CAD 30K of revenue over the trailing twelve months. 5 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: CAD 30K (to FY2024). Net income: −CAD 2.8M, trailing twelve months to FY2024. EPS: −CAD 0.65, trailing twelve months to FY2024.

DRUGBright Minds Biosciences Inc.

Healthcare

$52.26+2.8% 1Y

$52.26

$48.0952 weeks$95.99

DRUG as reported

Bright Minds Biosciences Inc. reported CAD 30K of revenue over the trailing twelve months. 5 reported series are charted on this page, each one as filed.

CAD 30K

Revenue, trailing twelve months · to FY2024 · every figure below is as filed, with no scoring applied

Net income: −CAD 2.8M
Net income · −62% year on year · trailing twelve months to FY2024
EPS: −CAD 0.65
EPS · −67% year on year · trailing twelve months to FY2024

Details›

Every series Ryufin has for DRUG, trailing twelve months
Series	Latest	Year on year	As of
Revenue	CAD 30K	n/a	FY2024
Net income	−CAD 2.8M	−62%	FY2024
EPS	−CAD 0.65	−67%	FY2024
ROE	−51%	n/a	FY2024
ROA	−46%	n/a	FY2024

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.